Moderna says its RNA vaccine was nearly 84% effective in preventing symptoms in adults 60 and older
Fox News
Moderna said a late-stage trial found that its vaccine for respiratory syncytial virus was 84% effective in preventing at least two symptoms in adults ages 60 and older.
There is no vaccine for adults currently on the market, but Moderna, Pfizer Inc. and GSK Plc. are each looking to be the first to release their RSV vaccines.
Pfizer and GSK filed applications for U.S. regulatory approval at the end of last year. Pfizer's RSV vaccine was reported to be 66.7% effective against two or more symptoms in late-stage trials.
More Related News